PPLPHARMAPiramal Pharma Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. The company was incorporated in 2020 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on PPLPHARMA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 17.4% YoY
- • Debt/Equity: 0.70
- • Promoter holding: 54.5%
- • Price vs SMA50: above
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
Bull case
- • Revenue growth: 17.4% YoY
- • Debt/Equity: 0.70
- • Promoter holding: 54.5%
- • Price vs SMA50: above
Bear case
- • Profit growth: -457.7% YoY
- • ROE: -4.0%
- • MACD: bearish
- • Price vs EMA21: below
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Profit growth: -457.7% YoY
- • ROE: -4.0%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹7.50). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.